Acrux reports on testosterone product trials
08 September, 2005 by Ruth BeranSpecialty pharmaceutical company Acrux (ASX:ACR) has reported positive results from two more clinical studies of its Testosterone MD-Lotion treatment for testosterone deficiency in men.
Ventracor recalls external components of VentrAssist
08 September, 2005 by Helen SchullerArtificial heart company Ventracor (ASX:VCR) has recalled the external components of its VentrAssist left ventricular assist system (LVAS) following the discovery of an anomaly in certain lots of the cable which connects the externally worn controller to the implanted VentrAssist blood pump.
Uniseed receives further $16m from founding investors
08 September, 2005 by Ruth BeranThe Universities of Queensland and Melbourne, the founding investors in university based pre-seed venture fund Uniseed, have extended their commitments to the fund by a further $8 million each.
New patents for Neuren
07 September, 2005 by Helen SchullerNeuren Pharmaceuticals (ASX:NEU) has been issued two additional US patents expanding its portfolio to Parkinson's disease and hypertension.
A sweet $22 million for Queensland research centre
07 September, 2005 by Helen SchullerGriffith University plans to almost triple its number of scientists from 55 to 155 over the next seven years to create the largest glycomics institute in the world following a commitment by the Queensland government and the university to spend AUD$22 million.
CSIRO develops sound technology for rapid screening
06 September, 2005 by Helen SchullerPoint-of-care blood screening at airports, schools and the local GP's office could be a reality following the development of a micro-technology at the CSIRO that uses sound to mix blood.
Eiffel hanging on as cash dwindles
05 September, 2005 by Helen SchullerSydney drug re-engineering company Eiffel Technologies (ASX:EIF) has released its results for the 2004-05 financial year, showing losses of AUD$3.5 million -- down 8.3 per cent from the previous year -- but less than $630,000 cash in the bank.
GTG lists on Nasdaq national market
05 September, 2005 by Ruth BeranMelbourne-based Genetic Technologies (ASX:GTG) has listed its Level II American Depositary Receipts (ADRs) on the US Nasdaq national market.
In brief: Avantogen, Novogen, Peplin, ResMed
02 September, 2005 by Staff WritersAlastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure.
US talks blamed for Avantogen price dip
01 September, 2005 by Ruth BeranStalled negotiations relating to Avantogen's (ASX:ACU) US$3 million instalment in its $5 million bid to acquire US vaccine developer Regalen, formerly Galenica Pharmaceuticals, may have caused its share price to slide from $0.19 on August 24 to $0.14 on August 31, the company said today in response to an ASX query.
Kryocor puts IPO on hold
01 September, 2005 by Ruth BeranMelbourne-based tissue engineering group Kryocor, which planned to close its IPO on March 31 and list on the ASX on April 14, has postponed its float and is considering its options.
Ministers on hand for science industry plan launch
01 September, 2005 by Susan WilliamsonAn 'action agenda' for the Australian science industry -- encompassing 47,000 manufacturers, distributors, laboratory services providers and researchers -- was launched in Sydney yesterday by the minister for industry, tourism and resources, Ian Macfarlane.
Nanomics readies first product for market
01 September, 2005 by Helen SchullerQueensland University spin-out Nanomics BioSystems has released its first product based on its proprietary second-generation ceramic nanoparticle technology.
Revenues up, loss down for ChemGenex
30 August, 2005 by Helen SchullerMelbourne- and California-based ChemGenex Pharmaceuticals (ASX:CXS) posted revenues of AUD$4.1 million, up 13.9 per cent and has reduced its loss by 8.7 per cent to $4.7 million for the year ending 30 June 2005.
Molloy to leave Biota, remain in US
29 August, 2005 by Ruth BeranBiota Holdings' (ASX:BTA) US-based CEO Peter Molloy has decided not to renew his contract in January 2006 following the company's decision to consolidate its operations back into its Melbourne facility.
